ADMA BIOLOGICS, INC.
ADMA$2.54B
Mid CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaRAMSEY
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
ADMA News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
RI-002
Primary Immune Deficiency Disorder
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
Primary Immune Deficiency Disorders (PIDD)
RI-001
Upper Respiratory Tract Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RI-002 | Phase 3 | Primary Immune Deficiency Disorder | - | - |
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] | Phase 3 | Primary Immune Deficiency Disorders (PIDD) | - | - |
RI-001 | Phase 2 | Upper Respiratory Tract Infection | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply